PAR AND SPECTRUM JOIN TO DISTRIBUTE GENERICS

Spectrum Pharmaceuticals will begindistribution of generic drugs produced byPar Pharmaceutical under a new strategicalliance agreed to by the 2 companies.Under the agreement, Par will makean unspecified equity investment inSpectrum, and Spectrum will receive paymentsbased on achievement of specifiedregulatory approvals that companyofficials believe to be worth over $10 million.Par will also provide financial andlegal support for the ongoing patentchallenge for sumatriptan injection—amigraine treatment originally developedby GlaxoSmithKline—and both companieswill share profits resulting from thesale of the generic products.